Skip to main content

Table 2 Percentage of patients achieving a response at Week 12 and Week 52 (NRI)

From: Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol

n (%) Week 12 Week 52
Placebo
+ NBBM
(n = 158)
CZP 200 mg Q2W
+ NBBM
(n = 159)
Placebo
+ NBBM
(n = 158)
CZP 200 mg Q2W
+ NBBM
(n = 159)
ASDAS-MI 10 (6.3) 56 (35.2) 11 (7.0) 75 (47.2)
ASAS40 18 (11.4) 76 (47.8) 25 (15.8) 90 (56.6)
BASDAI50 23 (14.6) 68 (42.8) 19 (12.0) 88 (55.3)
ASDAS-ID 2 (1.3) 26 (16.4) 6 (3.8) 44 (27.7)
  1. ASAS40 Assessment of SpondyloArthritis International Society 40%, ASDAS Ankylosing Spondylitis Disease Activity Score, ASDAS-ID ASDAS inactive disease (ASDAS <1.3), ASDAS-MI ASDAS major improvement (reduction in ASDAS ≥2.0), BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50%, NRI non-responder imputation, Q2W every 2 Weeks